Trial Title:
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
NCT ID:
NCT06521567
Condition:
Melanoma
Conditions: Official terms:
Melanoma
Dostarlimab
Conditions: Keywords:
Solid Tumours
Cobolimab
Dostarlimab
Study type:
Interventional
Study phase:
Phase 1/Phase 2
Overall status:
Not yet recruiting
Study design:
Allocation:
Non-Randomized
Intervention model:
Sequential Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
Cobolimab
Description:
Cobolimab will be administered
Arm group label:
Part 1- Dose determination
Arm group label:
Part 2- Dose expansion
Intervention type:
Drug
Intervention name:
Dostarlimab
Description:
Dostarlimab will be administered
Arm group label:
Part 1- Dose determination
Arm group label:
Part 2- Dose expansion
Summary:
The goal of this interventional study is to determine the strength of cobolimab and
dostarlimab that is most tolerated in children and young adults who have advanced solid
tumors. This study also aims: (a) to check if it is safe to use cobolimab and dostarlimab
combination in children and young adults, (b) to see how to manage the side effects that
may occur, and (c) the effect of this treatment in participants
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following
criteria apply:
- Participants between the age of 0 to not more than 21 years at the time of signing
informed consent form (ICF).
- Disease characteristics:
Part 1: Participants with advanced or metastatic solid tumors who have had disease
progression after treatment with available therapies that are known to confer clinical
benefit and who have limited available treatment options as determined by the
investigator. Additionally, exposure to prior immunotherapy or experimental therapies is
acceptable:
1. Melanoma
2. Hodgkin Lymphoma
3. High and Low Grade Glioma: including Glioblastoma multiforme (GBM), Diffuse
intrinsic pontine glioma (DIPG), and ependymoma.
4. Osteosarcoma
5. Hepatic tumors [including Hepatoblastoma, Hepatocellular carcinoma (HCC), and
Fibrolamellar carcinoma]
6. Rhabdomyosarcoma
Part 2:
1. Participants with Melanoma who have not received prior systemic therapy:
- Participants with BRAF gene, found on chromosome 7 (BRAF) mutations who are
eligible for a BRAF-targeted therapy are eligible if they qualify for
immunotherapy.
- Participants with locally treated and controlled metastatic CNS lesions without
leptomeningeal spread are eligible
2. Relapsed/refractory Hodgkin lymphoma (HL) that has failed at least 2 prior lines of
systemic therapy)
- Participants must have performance status ≥60% on the Karnofsky scale for
participants >16 years of age and ≥60% on the Lansky scale for participants ≤16
years of age.
- Adequate organ function as demonstrated by a complete blood count at screening
obtained without transfusion [platelets or red blood cells (RBC)] or receipt of
Colony stimulating factor (CSF), Granulocyte colony stimulating factor (G-CSF),
Granulocyte macrophage colony stimulating factor (GMCSF) or rErythropoeitin
(rEPO) within 2 weeks prior to screening.
- Adolescent participants who have entered puberty must consent (be willing) to
use of contraceptive measures, or refrain from sexual intercourse, if in line
with their usual practice, as well as sperm/egg donation for the duration of
treatment
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Medical conditions:
- Participant has uncontrolled CNS involvement by any tumor pathology
- Participant has a heart rate-corrected QT interval according to QTcF prolongation at
screening >470 msec or >480 msec for participants with bundle branch block.
- Participant has clinically significant cardiovascular disease Participant has
chronic respiratory disease Prior/ Concomitant therapy
- Has received treatment with an investigational agent within 21 days, or <5 times the
half-life of the most recent therapy prior to study Day 1, whichever is shorter.
- Has received systemic steroid therapy within 3 days prior to the first dose of the
study treatment or is receiving any other form of immunosuppressive medication.
Replacement therapy is not considered a form of systemic therapy. Use of inhaled
corticosteroids, local steroid injection, or steroid eye drops is allowed.
- Has not met the following waiting/washout periods for X-ray therapy (XRT) including
external beam radiation therapy/external beam irradiation including protons:
- Participant has had major surgery within 3 weeks prior to the first dose of study
treatment or has not adequately recovered from any AEs (Grade ≤1) and/or
complications from any major surgery. Surgical implantation of a port catheter is
not exclusionary.
- Prior Bone Marrow Transplant <60 days of screening. Prior/Concurrent clinical study
experience
- Is currently enrolled or has participated in any other clinical study involving an
investigational study or interventional medical research within 21 days or 5
half-lives, whichever is shorter, of an investigational medicinal product before
signing ICF Diagnostic assessments
- Has documented presence of Hepatitis B surface antigen (HbsAg) at Screening or
within 3 months prior to first dose of study intervention.
- Has a positive Hepatitis C virus (HCV) antibody test result at Screening or within 3
months prior to first dose of study intervention.
- Has a positive HCV Ribonucleic Acid (RNA) test result at Screening or within 3
months prior to first dose of study intervention.
- Has a known history of Human immunodeficiency virus (HIV) or has a HIV-positive test
result at Screening.
- Is pregnant or breastfeeding.
Gender:
All
Minimum age:
0 Years
Maximum age:
21 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
GSK Investigational Site
Address:
City:
West Hollywood
Zip:
90048
Country:
United States
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Leo Mascarenhas
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Iowa City
Zip:
52242-1009
Country:
United States
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
David Dickens
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Boston
Zip:
02115
Country:
United States
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Natalie Bucheimer Collins
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Hackensack
Zip:
07601
Country:
United States
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Katharine Offer
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Cincinnati
Zip:
45229
Country:
United States
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Joseph Pressey
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Providence
Zip:
02903
Country:
United States
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Bradley DeNardo
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Madison
Zip:
53792
Country:
United States
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Rebecca M. Richards
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Buenos Aires
Zip:
C1181ACH
Country:
Argentina
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Monika Makiya
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Buenos Aires
Zip:
C1428AQK
Country:
Argentina
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Agustin Cardoso
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Recife
Zip:
50070-550
Country:
Brazil
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Mecneide Mendes Lins
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Jaú
Zip:
17210-120
Country:
Brazil
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Larissa Moreira
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
São Paulo
Zip:
08270-070
Country:
Brazil
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Sidnei Epelman
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Barretos
Zip:
14784-400
Country:
Brazil
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Gisele Jorge
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Porto Alegre
Zip:
90035-003
Country:
Brazil
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Lauro José Gregianin
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Rio de Janeiro
Zip:
20230-130
Country:
Brazil
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Sima Esther Ferman
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Brno
Zip:
61300
Country:
Czechia
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Jaroslav Sterba
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Praha 5
Zip:
15006
Country:
Czechia
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
David Sumerauer
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Copenhagen
Zip:
2100
Country:
Denmark
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Mimi Kjaersgaard
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Lyon cedex 08
Zip:
69373
Country:
France
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Antony Ceraulo
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Marseille
Zip:
13005
Country:
France
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Nicolas André
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Paris Cedex 05
Zip:
75248
Country:
France
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Amaury Leruste
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Strasbourg
Zip:
67098
Country:
France
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Natacha Entz-Werle
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Villejuif
Zip:
94805
Country:
France
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Charlotte Rigaud
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Wuerzburg
Zip:
97080
Country:
Germany
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Paul-Gerhardt Schlegel
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Berlin
Zip:
13353
Country:
Germany
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Anne Thorwarth
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Hamburg
Zip:
20246
Country:
Germany
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Uwe Kordes
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Bologna
Zip:
40138
Country:
Italy
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Arcangelo Prete
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Roma
Zip:
00165
Country:
Italy
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Franco Locatelli
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Torino
Zip:
10126
Country:
Italy
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Franca Fagioli
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Napoli
Zip:
80123
Country:
Italy
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Massimo Abate
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Goyang-si
Zip:
10408
Country:
Korea, Republic of
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Jun Ah Lee
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Seoul
Zip:
03080
Country:
Korea, Republic of
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Hyoung Jin Kang
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Seoul
Zip:
03722
Country:
Korea, Republic of
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Jung Woo Han
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Seoul
Zip:
06351
Country:
Korea, Republic of
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Ji Won Lee
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Seoul
Zip:
138-736
Country:
Korea, Republic of
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Kyung Nam Koh
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Barcelona
Zip:
08035
Country:
Spain
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Lorena Valero Arrese
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Madrid
Zip:
28009
Country:
Spain
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Alba Rubio San Simón
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Madrid
Zip:
28046
Country:
Spain
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Antonio Pérez Martínez
Email:
Principal Investigator
Facility:
Name:
GSK Investigational Site
Address:
City:
Valencia
Zip:
46026
Country:
Spain
Contact:
Last name:
US GSK Clinical Trials Call Center
Phone:
877-379-3718
Email:
GSKClinicalSupportHD@gsk.com
Contact backup:
Last name:
EU GSK Clinical Trials Call Centre
Phone:
+44 (0) 20 8990 4466
Email:
GSKClinicalSupportHD@gsk.com
Investigator:
Last name:
Antonio Juan Ribelles
Email:
Principal Investigator
Start date:
September 13, 2024
Completion date:
October 17, 2030
Lead sponsor:
Agency:
GlaxoSmithKline
Agency class:
Industry
Source:
GlaxoSmithKline
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06521567
